Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

Sep 16, 2020
|
Christie Rizk
Premium

NEW YORK – A new startup called Stitch Bio is combining whole-genome sequencing, CRISPR technology, liquid biopsy, and gene therapy to target cancer cells with gene fusions in order to make them druggable. The company believes its approach is both applicable to a wide variety of cancers and highly precise and individualized.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Germany to Increase Viral Sequencing

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

Getting Used to It

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

Green Access at Science

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

Science Papers Examine Chronic Kidney Disease GWAS, Pneumonia Microbiome

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Jan
26
Featured Webinar

Panel Discussion: Genotyping by Sequencing for Novel SNP Discovery with Less Common Genomes

Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Gene Silencing/Gene Editing

  1. DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

  2. Mammoth Biosciences Taking Lead Role in DARPA-Funded Development of Pathogen Detection Tech

    Premium

  3. JumpCode Genomics Raises $21M in Series B Financing Round

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.